Fungal urinary tract infections are increasingly prevalent in the elderly in acute and chronic care settings. This randomized trial compares the efficacy and safety of oral fluconazole with the efficacy and safety of bladder irrigation with amphotericin B for treatment of funguria (~10,000 cfulmL of urine) in 109 hospitalized elderly patients. A second treatment course was given for persistent funguria. Indwelling bladder catheters were present in 69% of the patients. While Candida albicans was the predominant isolate from catheterized patients, C. albicans, Candida tropicalis, and Torulopsis glabrata were recovered from noncatheterized patients. Two days after completion of treatment, funguria was eradicated in 96% of the patients treated with amphotericin Band 73% of those treated with fluconazole (P < .05). At 1 month after study enrollment, the mortality rate associated with all causes was greater among patients who were treated with amphotericin B bladder irrigation than among those who received oral fluconazole therapy (41% vs. 22%, respectively; P < .05); this finding suggests that local therapy may beassociated with poorer survival. The proportion of patients without funguria at 1 month after study enrollment was similar in the two treatment groups (84%, amphotericin B group; 80%, fluconazole group). A few minor and mild adverse events occurred.
The finding of fungal growth in the urine, or funguria, has increased sharply because of the frequent use of broad-spectrum antibiotics, corticosteroids, and bladder catheters and because of prolonged hospitalizations [1] . The incidence of funguria in the elderly has increased dramatically, particularly in acute and chronic care settings [2, 3] . Patients with fungal urinary tract infection may be asymptomatic, have superficial colonization, or present with clinical manifestations of locally invasive infection, ascending infection, or disseminated infection. Despite a lack of consensus regarding the definition of fungal urinary tract infection [4] , treatment is often initiated for symptomatic or persistent funguria. Bladder irrigation with amphotericin B became standard therapy during the last two decades by virtue of widespread usage and has demonstrated efficacy in several uncontrolled studies [5] [6] [7] [8] [9] [10] . This treatment requires an indwelling bladder catheter for 2-14 days, which may produce discomfort and an increased risk for acquiring bacteriuria and necessitates significant nursing attention for its administration.
The development of new oral triazole antifungal agents has created the opportunity for comparing the risks and benefits of local vs. systemic therapy. Fluconazole is excreted primarily unchanged in the urine, has marked activity against most species of Candida, and has been reported to have few adverse effects [11] . A recent review of case reports and small studies of patients with funguria who were treated with fluconazole provided cumulative evidence of its effectiveness, although no larger clinical trials have been reported [12] . Because most patients treated for funguria in our institution are elderly [2] and because this infection represents a common clinical problem in the nursing home setting, we conducted a randomized trial comparing the efficacy and safety of oral fluconazole with amphotericin B bladder irrigation for treatment of older adults with funguria.
Methods Patient Selection
Hospitalized patients who were 65 years of age or older and had funguria were recruited for enrollment in this study. Potential subjects were identified from patients for whom urine cultures were ordered by their own physicians for clinical indications (such as fever, urinary symptoms, or urologic disease) and who were found to have funguria by the hospital laboratory. Four hundred four patients eligible for study entry had fungi in two consecutive urine specimens obtained at least 48 hours apart (but not more than I week apart, with the second specimen obtained within 48 hours of enrollment), cultures of which demonstrated fungal growth of~10,000 cfu/mL of urine. Fungal growth of~10,000 cfu/mL of urine was not detected in the initial screening. Patients were excluded from the study because ofthe following reasons: current treatment for funguria (75 patients), significant renal insufficiency with an estimated em 1996;22 (January) Treatment of Fungal UTI 31 creatinine clearance of < 11 mL/min (100), fungal sepsis during the hospital admission (4), inability to receive oral medication (6), AIDS or known hypersensitivity to fluconazole or amphotericin B (3), informed consent could not be obtained (61), or their physicians refused to allow participation according to the protocol (42). One hundred thirteen patients who met the criteria were enrolled in the study. Informed consent was obtained from all patients or their surrogates, and the study protocol was reviewed and approved by the institutional review board at our medical center.
Study Design
After obtaining informed consent, patients were randomly assigned to two treatment groups on a 1:1 ratio with use of a permuted block design stratified for the presence of an indwelling bladder catheter at the time of enrollment. Those patients with indwelling bladder catheters at the time of randomization had their catheters changed. All patients randomized to receive amphotericin B bladder irrigation had a three-way indwelling catheter inserted. All patients received a 5-day course of either amphotericin B (as a continuous bladder irrigation of 25 mg in 500 mL of 5% dextrose in water infused through a threeway indwelling bladder catheter at the rate of 42 mL/h) or oral fluconazole (as an initial 200-mg loading dose followed by 100 mg once daily [or 50 mg/d for patients with an estimated creatinine clearance of between 11 and 50 mL/min] for four subsequent days). This study was unblinded due to the difference in the method of drug delivery; there were no differences in the type of care either group received other than attention to maintenance of the bladder catheter (which may have been present in patients in either group) for the patients who had or required bladder catheters. Urine cultures were evaluated by hospital laboratory technicians who were unaware of the treatment group or clinical data.
After randomization, a brief chart review, patient interview, and physical examination were performed daily. Urine for cultures was obtained 2 days after completion of therapy (when it was assumed that all drugs would have been cleared) and again 1 month after enrollment. Urine cultures demonstrating fungal growth of ;;::-: 10,000 cfu/ml, were plated; the colony count was measured, and the species were identified. Patients whose urine cultures yielded persistent fungal growth (;;::-: 10,000 cfu/mL) after the initial course of therapy were retreated with the same drug regimen for an additional 5 days, and another urine specimen for culture was obtained 2 days after the second treatment course. Urine was obtained as voided, clean-catch specimens; sterile "in and out" specimens from catheters; or sterile syringe aspirates from indwelling bladder catheters. All cultures were plated (l: 1,000 inoculum), and the species of fungi and density of growth (cfu) were recorded.
The efficacy of the two drugs for treatment of funguria was determined by the results of the culture of urine obtained 2 days after the conclusion of therapy. These results were designated as follows: eradication of funguria (fungal growth of 0-10,000 cfu/mL of urine, which was not detected by our laboratory) or persistence of funguria (fungal growth of ;;::-: 10,000 cfu/mL of urine). The efficacy of the two drugs 1 month after study enrollment was a secondary aim of the study; results ofcultures of urine obtained at this time were designated as follows: absence of infection (0-10,000 cfu/mL of urine), persistence of infection (growth of ;;::-: 10,000 cfu of the same species of fungi/mL of urine), and reinfection (no funguria after treatment and growth of ;;::-: 10,000 cfu of any fungi/mL of urine at 1 month or growth of a species of fungi at 1 month different than what had been present after treatment). Absence of infection 1 month after study enrollment was further designated as sustained cure (eradication of infection after treatment) or spontaneous cure (persistent infection after treatment and no funguria at 1 month). Any further treatment with antifungal agents during the 1 month after enrollment was determined at the follow-up assessment.
Statistical Methods
The sample size was determined on the basis of the assumption that a difference of ;;::-: 15% in response rates among patients completing the 5-day regimen of treatment is clinically notable. We estimated a 75% vs. 90% difference in efficacy between treatment groups for the primary analysis 2 days after treatment such that 96 patients would be required per group (type I error, 0.05; two-tailed test with 80% power). It was assumed that the rate of withdrawal from the study would be <3% for the primary endpoint 2 days after treatment. The efficacy of the two drugs at 2 days after treatment and again at 1 month after study enrollment was determined by a two-tailed Fisher's exact test. Differences in distributions of the categories of outcomes (responses to treatment, which were determined by results ofurine culture as outlined above) were assessed by means of exact tests (Fisher's test or a similar test). Interim analyses were conducted with use of O'Brien-Fleming criteria [13] to preserve a level of significance of~.05 in the final analysis.
Results

Study Population
Informed consent was provided for a total of 113 patients, and these patients were randomized to treatment groups; four patients died during the night between the day of enrollment and the day of the initiation of drug therapy and were not included in the analysis. Of the 109 subjects who entered the treatment phase, 59 were randomized to treatment with amphotericin B bladder irrigation, and 50 were randomized to treatment with oral fluconazole. Our study sample consisted of hospitalized elderly patients with multiple comorbid conditions. There were no significant differences between the two Jacobs et al. groups with respect to patient characteristics (table 1) . Seventyone percent of the patients were women. Two-thirds of the patients had indwelling bladder catheters in use at the time of enrollment. They were well matched with regard to factors that could influence the response to treatment, such as diabetes mellitus, decubitus ulcers, and the use of indwelling bladder catheters and broad-spectrum antibiotics.
Clinical Characteristics
There were no significant differences in laboratory test results for the patients in the two treatment groups at baseline (table 2) . Fever was present in 26% of patients. Reports of dysuria, frequency of urination, urgency of urination, or lower abdominal pain were rare. Urinalysis revealed pyuria (greater than five leukocytes per high-power field) in both chronically catheterized patients (64%) and noncatheterized patients (53%), and a similar proportion of patients in both treatment groups had pyuria. Microscopic hematuria (greater than five erythrocytes per high-power field) was present in a similar percentage of patients with and without indwelling bladder catheters. Candida albicans was the fungus most frequently isolated from patients with indwelling bladder catheters. Candida tropicalis and Torulopsis glabrata were together more frequently recovered from patients who had not been previously catheterized than was C. albicans. The concentrations of fungal colonies in culture were similar for catheterized and noncatheterized patients; these concentrations did not vary significantly between the two specimens. A concomitant bacterial urinary tract infection, defined only by pyuria and significant bacteriuria (~100,000 cfu/mL of urine), was present at baseline in 29% of patients with indwelling bladder catheters and 12% of patients without catheters.
Clinical Outcomes
Urine specimens for cultures were obtained 2 days after the first course of therapy from 96 patients (51 in the amphotericin B group [6 had died; 2 were unavailable] and 45 in the fluconazole group [2 had died; 3 were unavailableD. Analysis of patients who completed the treatment and were evaluated by means of a urine culture at the conclusion of therapy revealed that, by 2 days after treatment, funguria was eradicated in 96% (49 of 51) ofthose patients treated with amphotericin B bladder irrigation and in 73% (33 of 45) of those patients treated with oral fluconazole (P < .05). On the basis of the statistical significance of the differences in rates of efficacy of the two drugs, the trial was terminated early. Criteria for stopping the trial were based on results from the efficacy analysis of 5-day treatment regimens with the expectation that the rate of withdrawal from the study would be <3%. During this analysis, eight patients (7%) died, and five patients (5%) were withdrawn before completion of the protocol for evaluation of efficacy at 7 days. Given that the rate of withdrawal was greater than the 3% expected, the decision to stop the trial was based on results ofthe efficacy analysis (unadjusted P value of .0026). Although the difference for the intent-to-treat analysis was not significant (P > .05), the type and amount of difference in the efficacy of the two drugs are similar by an efficacy analysis and an intent-to-treat analysis. In an intent-to-treat analysis (109 patients), the rate of eradication was 83% (49 of 59) among the amphotericin B group and 66% (33 of 50) among the fluconazole group (unadjusted P value of .0456).
Funguria was eradicated 2 days after treatment in a similar proportion of patients with (53 of 75) and without (29 of 34) chronic bladder catheterization. The rates of eradication were comparable between patients with and without pyuria (68% vs. 86%, respectively), with and without fever (68% vs. 78%, respectively), and with and without diabetes (74% vs. 76%, respectively). The proportion of patients for whom funguria due to C. albicans, C. tropicalis, and T. glabrata (the three most frequently identified organisms) was eradicated after the first course of therapy was similar. Funguria was eradicated after the first course of therapy and replaced by bacterial growth of> 10 5 cfu/mL in 28% (15 of 53) of patients with indwelling bladder catheters (7 of 33 in the amphotericin B group and 8 of 20 in the fluconazole group) and in 28% (8 of 29) of noncatheterized patients (5 of 16 in the amphotericin B group and 3 of 13 in the fluconazole group). The bacteria were di- (24) 3 (17) 6 (18) 3 (19) 28 (68) 9 (50) 22 (65) 5 (31) 8 (20) 7 (39) 8 (24) 7 (44) 2 (5) 2 (11) 1 (3) 4 (25) 1 (2) t Not identified to the species level.
verse. The following bacteria were isolated from catheterized patients: enterococci (6), Pseudomonas species (3), Escherichia coli (3), Klebsiella species (2), and Proteus species (1). The following bacteria were isolated from patients not previously catheterized: Pseudomonas species (3), enterococci (2), E. coli (2) , and Staphylococcus epidermidis (l). Nine of the 14 patients with persistent funguria after treatment were given a second course of the same treatment regimen (1 of2 in the amphotericin B group and 8 of 12 in the fluconazole group). The one patient treated with a second course of amphotericin B bladder irrigation continued to have persistent funguria. Funguria was eradicated in seven (88%) of the eight patients who received a second course of oral fluconazole treatment.
At 1 month after study entry, urine specimens for cultures were obtained from only 61 patients (31 in the amphotericin B group and 30 in the fluconazole group) (table 3). There was a significant difference in the rates of death (41% among the amphotericin B group vs. 22% among the fluconazole group; P = .042). The cause of death was not determined in most cases, many of which occurred in a nursing facility. Rates of study withdrawal, including death, were 47% among patients who received amphotericin B treatment and 40% among patients who received fluconazole treatment. None of the patients had received oral antifungal treatment or bladder irrigation during the interim period. Under an intent-to-treat analysis, at 1 month after study enrollment, there was no statistically significant difference in the percentage of patients who had a sustained cure in the two treatment groups (42% [ None of the deaths were thought to be associated with the study drugs. One fluconazole-treated patient had a rash after the first dose that necessitated discontinuation of therapy. The other four adverse events were considered minor and mild. Hematuria occurred in two patients treated with amphotericin B bladder irrigation. Nightmares and fatigue occurred in two separate patients treated with oral fluconazole. No adverse effects occurred in any of the patients who received a second course of treatment.
Discussion
Funguria, particularly candiduria, has been found to be increasingly prevalent in acute and chronic care settings [3, 14] . Hsu and Ukleja [7] reported that cultures of urine from 24.8% of nursing home residents with indwelling urethral catheters who were admitted to an acute care setting yielded Candida. This infection has been associated with the use of indwelling bladder catheters, broad-spectrum antibiotics, and immunosuppressive agents; advanced age; female gender; diabetes mellitus; and urologic anomalies [15] [16] [17] . As a result, funguria often occurs in the frail elderly patient, but the management of this infection remains a clinical dilemma for the treating physician. The finding of persistent fungi in the urinary tract is considered clinically significant [18] . Unlike bacterial infections, fungal infections of the urinary tract have not been consistently associated with pyuria, symptoms, or a defined concentration of organisms [1, 2, 5, [18] [19] [20] . The criteria that discriminate between fungal colonization and infection of the urinary tract remain undefined. Although urine specimens for culture were obtained from patients in this study for diagnostic purposes, the finding of funguria was frequently unexpected. Fever occurred in one-third ofthe patients, most of whom had no identified source other than bacterial urinary tract infection, which occurred in a small percentage of patients. In the present study, pyuria, fever, and hematuria were not consistently associated with funguria, were present in similar proportions of catheterized and noncatheterized patients, and did not correlate with a response to treatment. The colony count of fungi in urine cultures did not vary significantly between the two specimens obtained or between catheterized and noncatheterized patients, nor did it correlate with outcome. Many of the patients were unable to report symptoms.
The natural history of funguria is also uncertain. Several studies have suggested that funguria is benign and self-limiting and resolves with correction of predisposing conditions [1, 20, 21] . Other investigators have found an increase in mortality rates associated with candiduria, particularly in chronically ill patients [2, 6] , perhaps because ofthe development of candidemia. In >50% of patients with candidemia, candiduria is present [22, 23] . The presence of an indwelling bladder catheter is associated with a 13-fold increase in the odds of developing nosocomial candidemia [24] .
In a retrospective study of candiduria in 27 critically ill surgical patients, all of whom were treated with amphotericin B bladder irrigation for 7 days, 17 subsequently had candidemia (mortality rate, 33.3%) [25] . In a prospective arm of the study of critically ill surgical patients, 20 patients with candiduria and clinical evidence of sepsis were treated with intravenous fluconazole; in all patients, eradication of candiduria occurred, and there was no evidence of candidemia (mortality rate, 5%). Although the characteristics of our patients are quite different from those of the surgical patients, the mortality rate among patients treated with amphotericin B was 41%, and the mortality rate among patients treated with fluconazole was 22%.
We previously reported a mortality rate of 30.5% among a group of patients without funguria who were matched for age and length of hospital stay with patients with funguria in our institution [2] . The increased mortality rate among the patients in our study who were randomized to receive amphotericin B bladder irrigation suggests that local (intravesical) therapy may fail to eradicate fungi harbored in the upper urinary tract or elsewhere that subsequently cause sepsis and death. If verified, this hypothesis would support the finding of Nassoura et al. [25] of a significant rate of candidemia in critically ill patients 9.9 days after diagnosis of funguria despite treatment with amphotericin B bladder irrigation. No data from blood cultures or autopsies were obtained in our study; therefore, we cannot substantiate this hypothesis. It was the perception of the staff caring for these patients (in the home or in a nursing home) that the deaths were due to comorbid disease and that they were not unexpected. In fact, the finding of funguria in this elderly population with multiple comorbid conditions almost appeared to be a marker of significant risk for mortality, perhaps reflecting a state of failing immunologic function.
C. albicanswas primarily isolated from catheterized patients, whereas C. albicans, C. tropicalis, and T. glabrata were isolated in similar proportions from noncatheterized patients. This difference in isolates may represent a dissimilarity in the pathophysiology of funguria in catheterized and noncatheterized individuals that may have implications in the natural history and response to treatment of this infection. Although we did not find a difference in outcome after treatment between previously catheterized and noncatheterized patients, other investigators have reported lower eradication rates among patients with indwelling urinary catheters [26, 27] .
In a randomized clinical trial, we compared two drug regimens for the treatment of fungal urinary tract infections in hospitalized frail elderly patients who had significant renal insufficiency and serious comorbid conditions. Both treatment regimens had notable clinical efficacy 2 days after treatment and I month after study entry and were associated with few adverse events. Because of the invasive nature of administration of amphotericin B bladder irrigation (which is likely to require hospitalization and added resources, e.g., personnel and materials for administration), fluconazole emerges as an attractive alternative drug for initial treatment of fungal urinary tract infections, and amphotericin B bladder irrigation could be reserved for patients for whom this treatment fails. However, a note of caution must be made in recommending the frequent use of systemic therapy for funguria because of the potential of inducing resistance to the agent. Sensitivity testing was not undertaken in this study, but most of the isolates recovered were ones that are infrequently resistant to fluconazole or amphotericin B in patients who have not been previously treated. The duration oftreatment was brief, thus making the emergence of resistance less likely.
